Antioxidant sestrin-2 redistribution to neuronal soma in human immunodeficiency virus-associated neurocognitive disorders

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 3, 2012, Pages 579-590

  Soontornniyomkij, Virawudh ^a   Soontornniyomkij, Benchawanna ^a   Moore, David J ^a   Gouaux, Ben ^a   Masliah, Eliezer ^b   Tung, Spencer ^c   Vinters, Harry V ^c   Grant, Igor ^a   Achim, Cristian L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; HIV dementia; Neurofibrillary pathology; Oxidative stress; SESN2

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIOXIDANT; ANTIRETROVIRUS AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; SESTRIN 2; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED NEUROCOGNITIVE DISORDER; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NEOCORTEX; NEUROLOGIC DISEASE; NEUROPIL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AIDS DEMENTIA COMPLEX; ANTIOXIDANTS; BRAIN; COGNITION DISORDERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEURONS; NUCLEAR PROTEINS;

EID: 84866113654     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-012-9357-0     Document Type: Article

References (46)

1. Aksenov MY, Hasselrot U, Bansal AK et al (2001) Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci Lett 305:5-8
2. Alafuzoff I, Arzberger T, Al-Sarraj S et al (2008) Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 18:484-496
3. Altman DG (1991) Comparing groups-categorical data. In: Practical statistics for medical research, 1st edn. Chapman and Hall, London, pp 261-265
4. Antinori A, Arendt G, Becker JT et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-1799 (Pubitemid 350059308)
5. Bandaru VV, McArthur JC, Sacktor N, Cutler RG, Knapp EL, Mattson MP, Haughey NJ (2007) Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology 68:1481-1487 (Pubitemid 46685918)
6. Budanov AV (2011) Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid Redox Signal 15:1679-1690
7. Budanov AV, Karin M (2008) p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134:451-460
8. Budanov AV, Shoshani T, Faerman A et al (2002) Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene 21:6017-6031
9. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM (2004) Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304(5670):596-600 (Pubitemid 38541920)
10. Deshmane SL, Mukerjee R, Fan S et al (2009) Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem 284:11364-11373
11. Furuta A, Price DL, Pardo CA, Troncoso JC, Xu ZS, Taniguchi N, Martin LJ (1995) Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 146:357-367
12. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A (1995) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 45:461-466
13. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J (1996) Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 153:1195-1201 (Pubitemid 26299841)
14. Haughey NJ, Cutler RG, Tamara A et al (2004) Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55:257-267 (Pubitemid 38167003)
15. Heaton RK, Franklin DR, Ellis RJ et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3-16
16. Jayadev S, Garden GA (2009) Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol 4:175-189
17. Kruman II, Nath A, Mattson MP (1998) HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 154:276-288 (Pubitemid 29044201)
18. Lee HP, Zhu X, Casadesus G et al (2010a) Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 10:1201-1208
19. Lee JH, Budanov AV, Park EJ et al (2010b) Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327(5970):1223-1228
20. Levine AJ, Hinkin CH, Ando K et al (2008) An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol 30:836-843
21. Li W, Malpica-Llanos TM, Gundry R, Cotter RJ, Sacktor N, McArthur J, Nath A (2008) Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology 70:1753-1762 (Pubitemid 351653962)
22. Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85:3036-3040 (Pubitemid 350057358)
23. Manda KR, Banerjee A, Banks WA, Ercal N (2011) Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radic Biol Med 50:801-810
24. McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543-555 (Pubitemid 41139976)
25. Nath A, Hersh LB (2005) Tat and amyloid: multiple interactions. AIDS 19:203-204 (Pubitemid 40409539)
26. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J (2008) Evolution of HIV dementia with HIV infection. Int Rev Psychiatr 20:25-31 (Pubitemid 351196197)
27. Navarro A, Boveris A, Bández MJ, Sánchez-Pino MJ, Gómez C, Muntané G, Ferrer I (2009) Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic Biol Med 46:1574-1580
28. Nunomura A, Perry G, Aliev G et al (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759-767 (Pubitemid 32678256)
29. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65:631-641 (Pubitemid 44297254)
30. Opii WO, Sultana R, Abdul HM, Ansari MA, Nath A, Butterfield DA (2007) Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2',3'-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol 204:29-38 (Pubitemid 46330254)
31. Papadia S, Soriano FX, Léveillé F et al (2008) Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11:476-487 (Pubitemid 351441886)
32. Pappolla MA, Omar RA, Kim KS, Robakis NK (1992) Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol 140:621-628
33. Robins LN, Wing J, Wittchen HU et al (1988) The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069-1077 (Pubitemid 19005460)
34. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11:1306-1313 (Pubitemid 41752911)
35. Schweinsburg BC, Taylor MJ, Alhassoon OM et al (2005) Brain mitochondrial injury in human immunodeficiency virusseropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 11:356-364 (Pubitemid 41614515)
36. Silverstein PS, Shah A, Gupte R, Liu X, Piepho RW, Kumar S, Kumar A (2011) Methamphetamine toxicity and its implications during HIV-1 infection. J Neurovirol 17:401-415
37. Smith MA, Zhu X, Tabaton M et al (2010) Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheim Dis 19:363-372
38. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:7-35
39. Soontornniyomkij V, Lynch MD, Mermash S, Pomakian J, Badkoobehi H, Clare R, Vinters HV (2010a) Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol 20:459-467
40. Soontornniyomkij V, Risbrough VB, Young JW, Wallace CK, Soontornniyomkij B, Jeste DV, Achim CL (2010b) Short-term recognition memory impairment is associated with decreased expression of FK506 binding protein 51 in the aged mouse brain. Age (Dordr) 32:309-322
41. Steiner J, Haughey N, Li W et al (2006) Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal 8:2089-2100 (Pubitemid 46489633)
42. Turchan J, Pocernich CB, Gairola C (2003) Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60:307-314 (Pubitemid 36152028)
43. Valcour V, Shiramizu B (2004) HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion 4:119-129 (Pubitemid 39549801)
44. Wallace DR, Dodson S, Nath A, Booze RM (2006) Estrogen attenuates gp120-and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59:51-60 (Pubitemid 41706154)
45. Yamamoto BK, Moszczynska A, Gudelsky GA (2010) Amphetamine toxicities: classical and emerging mechanisms. Ann N YAcad Sci 1187:101-121
46. Zhang X, Banerjee A, Banks WA, Ercal N (2009) N-acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells. Brain Res 1275:87-95